MILAN, July 03, 2024 (GLOBE NEWSWIRE) -- GTP Bioways Group is a French company operating as Biotech CDMO (Contract Developing and Manufacturing Organisation), specialising in R&D Services, process development and production of mAbs, enzymes, proteins, nanodrugs, ADCs and F&F. GTP Bioways Group, with multiple locations across France, specializes in delivering comprehensive services to biopharmaceutical companies. From preclinical development to commercial stages, the group focuses on utilizing cutting-edge technologies to advance innovative therapies.
GTP Bioways Group's services are seamlessly integrated with those of the Olon Biotech division. This integration enables Olon Biotech to expand and diversify its technological offerings, supporting every stage of the lifecycle, from R&D and preclinical phases to industrialization, through microbial and mammalian fermentation and biotherapeutics. Additionally, Olon Biotech will provide comprehensive services for the development and production of innovative ADC classes, offering a complete solution from mAbs to linkers, payloads, conjugation, and fill-and-finish processes.
GTP Bioways operates a total of four sites in France (Toulouse, Labege, Veyre-Monton, and Saint-Julien-en-Genevois) focused on development, clinical trial and cGMP manufacturing. The headquarters are based in Toulouse.
The four centers operate according to the highest quality standards, in line with reference GMPs and are regularly inspected by the relevant regulatory authorities.
The business areas on which GTP Bioways focuses include biologics manufacturing and ADC manufacturing (using mammalian and microbial fermentation technology), nanodrug manufacturing, fill and finish and analytical development – including HCP and immuno assay. In particular, the company has consolidated a strong expertise in the business areas in which it operates. Evidenced by a significative number of successfully developed biological processes, the management of a broad and diversified range of expression systems (mammalian, bacterial, yeast, insect cells) and molecules (mAbs, antibody fragments, cytokines, fusion proteins, enzymes, antigens). In addition, the group possesses significant expertise in bioconjugation and fill & finish. The CDMO services offered make up an integrated platform capable of supporting customers from drug discovery, through the entire development process with a special focus on the pre-clinical phase, phase I and phase II.
Since its foundation, Olon Group has consistently pursued a strategy of growth, consolidation, and global market expansion through both internal development and strategic acquisitions. Each acquired business has contributed valuable expertise, enhancing Olon's technological capabilities. In line with this strategy and aiming to advance its innovative and high-tech offerings to customers, Olon has acquired GTP Bioways Group. GTP Bioways Group’s specific capabilities in fully supporting CDMO biotechnology projects also in the early phase of new molecule development (pre-clinical, phase I and phase II), perfectly complements Olon's current assets, to enrich and broaden the offering to customers.
“The acquisition of GTP Bioways Group implies a strong and significant strengthening of Olon's service pipeline with the aim of creating new business opportunities, acquiring new customers and high-potential market areas, and ultimately continuing the company's growth,” stated Paolo Tubertini, CEO, Olon Group.
In Q3 2024, Olon will finalise its €25m investment in a facility operating under extremely high containment, fully dedicated to the development and the production of Ultra High Potent API - payloads and payload-linkers for antibody-drug conjugates (ADCs). Olon relies on more than four decades of experience in manufacturing cytotoxic products. With the acquisition of GTP Bioways, Olon Biotech will be able to offer full services for the development and production of ADCs, capable of supplying everything from mAbs to linkers, payloads, conjugation and fill and finish.
Contact info - Sabrina Spina, Olon Press Office. sspina@olonspa.it / +39 338 6674289
-
“加钱姐”徐冬冬喜提百花奖提名,最佳女配角逐再添实力战将近日,备受瞩目的第37届大众电影百花奖公布各大奖项的初评入围名单,其中,实力派演员徐冬冬凭借在电影《三大队》中的精湛表现,成功入围最佳女配角奖。在电影《三大队》2024-07-04
-
佳沛全球团队参观考察万纬上海临港园区2024年7月2日,万纬上海临港园区迎来了一批特别的访客——佳沛新西兰总部团队、欧洲佳沛团队以及来自全球多个国家的经销商代表,共计80余人走进万纬,实地参2024-07-04
-
周至县卫健局、县中医医院调研西安区域医学检验中心为进一步推动优质医技资源下沉基层、均衡布局,2024年7月3日,周至县卫生健康局计生协会会长李西成,周至县中医医院党总支书记李萌,副院长姬云峰,检验科主任张丽萍等一行2024-07-04
-
黄埔江畔群星聚,百年外滩风云起:百位KOL共鉴BE范德安雄厚品牌力7月2日,夜幕深垂,华灯初绽。上海外滩,这片融汇古今、百年风华的圣地,再度成为时尚界万众瞩目的焦点。 「BE范德安」,在此以一场名为“海洋生色·2024-07-04
-
《孤战迷城》热播,周纪伟演技松弛感绝了!让人又恨又心疼他近日,由黄景瑜、辛芷蕾领衔主演的电视剧《孤战迷城》正在爱奇艺、腾讯视频热播中,与以往的谍战剧不同的是,《孤战迷城》利用明暗身份对调、攻守阵营转换的叙事视角,为2024-07-04